Tags

Type your tag names separated by a space and hit enter

Pathophysiology of levodopa-induced dyskinesia: potential for new therapies.
Nat Rev Neurosci. 2001 Aug; 2(8):577-88.NR

Abstract

Involuntary movements--or dyskinesias--are a debilitating complication of levodopa therapy for Parkinson's disease, and is experienced in most patients. Despite the importance of this problem, little was known about the cause of dyskinesia until recently; however, this situation has changed significantly in the past few years. Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems.

Authors+Show Affiliations

Bezard E
Basal Gang, Laboratoire de Neurophysiologie, CNRS UMR 5543, Université Victor Segalen Bordeaux 2, 146 rue Léo Saignat, 33076 Bordeaux Cedex, France.
Brotchie JM
No affiliation info available
Gross CE
No affiliation info available

MeSH

AnimalsAntiparkinson AgentsBasal GangliaDisease Models, AnimalDopamineDyskinesia, Drug-InducedHumansLevodopaParkinson Disease

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't
Review

Language

eng

PubMed ID

11484001

Citation

Bezard, E, et al. "Pathophysiology of Levodopa-induced Dyskinesia: Potential for New Therapies." Nature Reviews. Neuroscience, vol. 2, no. 8, 2001, pp. 577-88.
Bezard E, Brotchie JM, Gross CE. Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nat Rev Neurosci. 2001;2(8):577-88.
Bezard, E., Brotchie, J. M., & Gross, C. E. (2001). Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. Nature Reviews. Neuroscience, 2(8), 577-88.
Bezard E, Brotchie JM, Gross CE. Pathophysiology of Levodopa-induced Dyskinesia: Potential for New Therapies. Nat Rev Neurosci. 2001;2(8):577-88. PubMed PMID: 11484001.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Pathophysiology of levodopa-induced dyskinesia: potential for new therapies. AU - Bezard,E, AU - Brotchie,J M, AU - Gross,C E, PY - 2001/8/3/pubmed PY - 2001/9/8/medline PY - 2001/8/3/entrez SP - 577 EP - 88 JF - Nature reviews. Neuroscience JO - Nat Rev Neurosci VL - 2 IS - 8 N2 - Involuntary movements--or dyskinesias--are a debilitating complication of levodopa therapy for Parkinson's disease, and is experienced in most patients. Despite the importance of this problem, little was known about the cause of dyskinesia until recently; however, this situation has changed significantly in the past few years. Our increased understanding of levodopa-induced dyskinesia is not only valuable for improving patient care, but also in providing us with new insights into the functional organization of the basal ganglia and motor systems. SN - 1471-003X UR - https://www.unboundmedicine.com/medline/citation/11484001/Pathophysiology_of_levodopa_induced_dyskinesia:_potential_for_new_therapies_ L2 - https://doi.org/10.1038/35086062 DB - PRIME DP - Unbound Medicine ER -